In order to participate in this study, you must be able to speak and read Dutch fluently.

The research drug T-817MA is a new drug against Alzheimer’s disease. With this study, the researchers want to find out more about the safety and effectiveness of the drug.

You visit our research center every twelve weeks where you receive T-817MA tablets or placebo tablets. Half of the participants will receive the study drug and the other half the placebo. During a few visits, questionnaires will be done, blood tests and physical examinations will take place, and MRI scans and EEGs will be done. The period in which you receive the research drug is eighteen months.

This study is commissioned by Toyama.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

During three visits in a maximum period of six weeks, it will be determined whether you meet the study criteria and whether your health allows participation in the study. If so, you may participate in the study. The selection includes blood tests, physical examinations, memory tests, questionnaires, an MRI scan, an EEG, and a spinal tap.

After completing the treatment phase, participants will be followed for up to six weeks and will return to the center once for a final check-up. During this last check-up visit, questionnaires and tests will be done for your memory, among other things, a final blood test, physical examination, and a spinal tap will be performed.

A total of 14 visits were made to the research center over a period of 6 weeks (screening) and 48-96 weeks (treatment).

• You have a diagnosis of Mild Cognitive Impairment (MCI) or mild-stage Alzheimer’s disease
• You are between 50-80 years old
• Use of Alzheimer’s medication is permitted, provided it has been the same dose for more than three months.
• You have a family carer who can accompany you during a few visits to the research center and answer questions about your health and functioning, among other things.